

Effectiveness of Extended-release Buprenorphine in Opioid Use Disorder: Results from NIDA CTN studies

Chair: Geetha Subramaniam, MD, DLFAPA, DFAACAP

57th ASAM Annual Conference, San Diego, CA



Disclosure Information

☀️ Geetha Subramaniam - No Disclosures

NIDA's Clinical Trials Network

Appalachian Node

University of Pittsburgh

Big South/West Node

UT Southwestern Medical Center
University of California, Los Angeles

Clinical Coordinating Center

The Emmes Corporation

Data & Statistics Center

The Emmes Corporation

Florida Node Alliance

University of Miami
Columbia University

Great Lakes Node

University of Illinois Chicago
Research Triangle Institute
Howard University

Greater Intermountain Node

University of Utah

Greater Southern California Node

University of California, Los Angeles

Health Systems Node

Kaiser Foundation Hospitals

New England Consortium

Yale University
McLean Hospital

New York Node

New York University
Columbia University

Northeast Node

Dartmouth College

Northstar Node

Hennepin Healthcare Research Institute

Ohio Valley Node

University of Cincinnati

Pacific Northwest Node

University of Washington
Washington State University

Southwest Node

University of New Mexico
Arizona State University

Southern Consortium Node

Medical University of South Carolina

Western States Node

Oregon Health & Science University
Stanford University



CTN Research Portfolio: Cascade Of Care Model

Risk Identification

CTN Study	Intervention
TAPS, S2BI	Screening tool
PHARMSCREEN	Pharmacy-Based
CDS	Clinical decision
STOP	Prevention of

Engagement and Linkage to MOUD

CTN Study	Intervention
SWIFT	Rapid XR-NTX
EXHIT ENTRE	XR-BUP initiation
	Consultation se
HI-SIRI	Integrated SUD
ED-INNOVATION	XR-BUP initiation
CO-CARE	Collaborative c

Retention in Treatment/Recovery

CTN Study	Intervention
RDD (Retention Phase)	High dose SL-BUP
	XR-BUP
	Digital therapeutic
MOMs	XR-BUP in pregnancy
Office-Based Methadone vs. Buprenorphine	Office-based methadone